Angiosarcoma Clinical Trial
Official title:
Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma
To find the highest tolerable dose of an mRNA vaccine that can be safely given to patients with cutaneous angiosarcoma
Objectives: Primary objective: •To determine the safety, toxicity, and feasibility of delivering autologous dendritic cells (DCs) loaded with tumor lysate plus mRNA to patients with cutaneous head & neck angiosarcoma as adjuvant therapy. Secondary objective: • To assess the recurrence free survival and overall survival in treated patients in order to make initial assessment of activity of this therapeutic approach Exploratory Objectives: • To quantitate immune responses in patients who receive autologous DCs loaded with tumor lysate plus mRNA ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
| Completed |
NCT01303497 -
Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas
|
Phase 2 | |
| Recruiting |
NCT02625389 -
Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization.
|
Phase 4 | |
| Completed |
NCT04293289 -
Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma
|
N/A | |
| Recruiting |
NCT05859074 -
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT02732678 -
Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04055220 -
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
|
N/A | |
| Recruiting |
NCT06375941 -
Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars
|
||
| Withdrawn |
NCT05116800 -
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
|
Phase 2 | |
| Recruiting |
NCT01042379 -
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01786889 -
Identification, Molecular Epidemiology Angiosarcoma of the Liver France
|
N/A | |
| Terminated |
NCT02212015 -
Evaluation of Votrient in Angiosarcoma
|
Phase 2 | |
| Active, not recruiting |
NCT02834013 -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT03331250 -
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
|
Phase 2 | |
| Completed |
NCT02584309 -
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
|
Phase 2 | |
| Not yet recruiting |
NCT06277154 -
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
|
Phase 2 | |
| Withdrawn |
NCT04607200 -
AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
|
Phase 2 | |
| Completed |
NCT04518124 -
Propranolol in Angiosarcoma
|
Phase 2 | |
| Recruiting |
NCT05961761 -
Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients
|
Phase 2 | |
| Completed |
NCT00887809 -
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
|
Phase 2 |